The Clav Protocol: Retatrutide Dose Escalation Reference

Retatrutide Dose Escalation: The Complete Reference

Retatrutide (LY3437943) is the first triple-agonist (GLP-1 / GIP / glucagon receptor) weight-loss compound to reach registrational Phase 3 trials. The dose-escalation schedule isn't arbitrary — it's the exact protocol Eli Lilly's investigators used in the Phase 2 trial published by Ania M. Jastreboff and colleagues in The New England Journal of Medicine (2023), and carried into the TRIUMPH Phase 3 program that reported topline results in December 2025.

This reference compiles the published escalation schedule, the GI tolerability data that justifies it, full reconstitution math for every vial size on the market, and the concurrent-compound context from the Clavicular looksmaxxing protocol. Every figure is sourced from the primary literature — links at the bottom of the page. All information here is for laboratory-research reference only.

Table of Contents

• Why Escalation Matters — The Published Evidence
• The Phase 2 Escalation Schedule
• Phase 3 (TRIUMPH-4) Confirms the Pattern
• Gastrointestinal Side-Effect Data
• Reconstitution Worksheet — Every Vial Size
• Unit-Syringe Dosing Math
• Storage, Stability, and Handling
• The Clavicular Concurrent-Compound Stack
• BPC-157 — Concurrent GI Protection
• References & Further Reading

Why Escalation Matters — The Published Evidence

The original Phase 2 investigation tested six retatrutide dosing arms: 1 mg, 4 mg (starting 2 mg), 4 mg (starting 4 mg), 8 mg (starting 2 mg), 8 mg (starting 4 mg), and 12 mg (starting 2 mg). The investigators specifically compared two starting approaches for the same target dose in the 4 mg and 8 mg groups — some participants initiated at 2 mg, others at 4 mg.

The finding that shaped every subsequent protocol: initiating at the lower 2 mg dose and escalating more gradually produced significantly fewer gastrointestinal adverse events while achieving equivalent weight loss at 48 weeks. Starting fast didn't produce faster results; it only produced more nausea, vomiting, and diarrhea during the first 8–12 weeks.

This is the reason the Clav protocol — and every subsequent retatrutide protocol derived from published literature — initiates at 2 mg weekly and escalates every 4 weeks.

The Phase 2 Escalation Schedule

From Jastreboff AM, Kaplan LM, Frías JP, et al. (NEJM 2023):

Phase

Week Range

Weekly Dose

Purpose

Initiation	Weeks 1–4	2 mg	Receptor adaptation, GI tolerability baseline
Escalation 1	Weeks 5–8	4 mg	First dose increment at 4-week minimum
Escalation 2	Weeks 9–12	8 mg	Mid-range efficacy onset
Maintenance	Weeks 13+	8 mg or 12 mg	Target dose per Phase 2 arm

Key rule from the published protocol: dose escalation occurs every 4 weeks, not sooner. The 4-week interval allows GLP-1 / GIP / glucagon receptor adaptation and is the minimum window at which GI AE incidence drops to a new stable baseline.

The Phase 2 trial ran escalation over up to 12 weeks total before participants reached their assigned maintenance dose. A participant targeting the 12 mg arm therefore spent three months escalating (2 → 4 → 8 → 12 mg) before ever reaching full-dose maintenance.

Phase 3 (TRIUMPH-4) Confirms the Pattern

The Phase 3 TRIUMPH-4 trial, reported by Eli Lilly in December 2025 and covered in HCPLive and Rheumatology Advisor, used the same 4-week escalation cadence. TRIUMPH-4 enrolled 1,880 adults with obesity and knee osteoarthritis and reported:

• Weight reduction of up to 28.7% at 68 weeks (12 mg arm, open-label extension) — the largest placebo-adjusted reduction observed in any obesity pharmacotherapy trial to date
• Baseline mean weight 112.7 kg (248.5 lbs); mean absolute reduction 32.3 kg (71.2 lbs) in the top arm
• WOMAC knee pain reduction of up to 4.5 points (75.8%) — a secondary outcome that triggered knee-OA labeling interest
• Non-HDL cholesterol and systolic blood pressure both reduced alongside weight loss

The TRIUMPH-4 trial did NOT find a shortcut to escalation. The slower ramp remained the standard of care.

Gastrointestinal Side-Effect Data

The TRIUMPH-4 Phase 3 safety population reported the following AE rates across all retatrutide arms combined:

Event

Retatrutide (pooled)

Placebo

Nausea	43%	7%
Vomiting	21%	2%
Diarrhea	33%	10%
Constipation	17%	6%	The Phase 2 Jastreboff NEJM paper reported similar directional patterns at the highest dose arms, with GI events concentrated during the escalation windows (weeks 1–12) and tapering substantially after participants reached a stable maintenance dose. What this implies for the Clav protocol: expect nausea during the first 2–4 weeks of each new dose step. It is not a signal that the compound isn't working — it is the documented expected adaptation window. If nausea is severe at week 5 (first escalation to 4 mg), the published protocol supports remaining at 2 mg for an additional 4 weeks before advancing. GET THE STACK Shop the Clav Protocol Research-grade Retatrutide, BPC-157, GHK-CU, SNAP-8 from Phiogen — every compound in the Clavicular protocol. Full Protocol GuideRetatrutide — N/A Reconstitution Worksheet — Every Vial Size Retatrutide ships as a lyophilized powder. It requires reconstitution with bacteriostatic water (BAC water — sterile water with 0.9% benzyl alcohol preservative, which allows multi-draw use from a single vial for up to 28 days refrigerated). The concentration you choose is a tradeoff between syringe draw volume (more dilute = larger volumes = easier to measure small doses) and vial longevity (more concentrated = smaller draw volumes = longer vial life). Two common targets: Target 1: 3 mg/mL (high volume, easier dose measurement — Clav protocol default)	Vial Size	BAC Water	Final Concentration	Draw for 2 mg	Draw for 4 mg	Draw for 8 mg

10 mg

3.3 mL

3 mg/mL

0.67 mL

1.33 mL

2.67 mL

15 mg

5 mL

3 mg/mL

0.67 mL

1.33 mL

2.67 mL

30 mg

10 mL

3 mg/mL

0.67 mL

1.33 mL

2.67 mL

Target 2: 5 mg/mL (smaller draw volumes, longer vial life)

Vial Size

BAC Water

Final Concentration

Draw for 2 mg

Draw for 4 mg

Draw for 8 mg

10 mg	2 mL	5 mg/mL	0.40 mL	0.80 mL	1.60 mL
15 mg	3 mL	5 mg/mL	0.40 mL	0.80 mL	1.60 mL
30 mg	6 mL	5 mg/mL	0.40 mL	0.80 mL	1.60 mL

Reconstitution Procedure (Step-By-Step)

• Warm both vials to room temperature (15–20 min on the counter). Cold BAC water injected into a cold peptide vial can slow dissolution.
• Swab both vial septums with 70% isopropyl alcohol. Allow to air-dry.
• Draw BAC water into a sterile syringe. Use the calculated volume from the table above.
• Inject slowly against the glass wall of the peptide vial — not directly onto the lyophilized cake. Direct impact can denature peptide structure via shear stress.
• Swirl gently — rolling the vial between your palms for 30–90 seconds. Do NOT shake. Shaking introduces foam and can damage peptide bonds.
• Verify the solution is clear. A cloudy or particulate-laden solution indicates denaturation or contamination; discard.
• Label the vial with the date of reconstitution, final concentration, and compound name.
• Refrigerate (2–8 °C / 36–46 °F) immediately after reconstitution.

Unit-Syringe Dosing Math

Most researchers use U-100 insulin syringes (100 units per 1 mL). The conversion is straightforward but worth spelling out:

1 mL = 100 units on a U-100 syringe

At 3 mg/mL concentration:

Target Dose

Volume

Insulin-Syringe Units

1 mg	0.33 mL	33 units
2 mg	0.67 mL	67 units
4 mg	1.33 mL	133 units (split into 2 draws or use a 2 mL syringe)
8 mg	2.67 mL	267 units (use a 3 mL luer syringe)	At 5 mg/mL concentration:	Target Dose	Volume	Insulin-Syringe Units

1 mg	0.20 mL	20 units
2 mg	0.40 mL	40 units
4 mg	0.80 mL	80 units
8 mg	1.60 mL	160 units (use two syringes or a larger-volume syringe)	Practical note: at target doses above ~4 mg per injection, the draw volume exceeds a single U-100 insulin syringe's capacity. Standard research protocols split into two draws or switch to a larger-gauge syringe. The 5 mg/mL concentration keeps most escalation volumes within a single U-100 syringe through week 12. Storage, Stability, and Handling	State	Temperature	Container	Published Stability

Lyophilized powder (sealed)	Room temp, dark, dry	Original vial	12+ months (per supplier CoA)
Lyophilized powder (sealed, refrigerated)	2–8 °C	Original vial	24+ months
Reconstituted in BAC water	2–8 °C	Original vial, upright	28–60 days (28 days conservative; industry standard)
Reconstituted (travel)	< 30 °C for < 4 h	Insulated carrier	Single-trip handling; return to refrigeration	Never freeze reconstituted peptide. Freeze-thaw cycles fracture peptide bonds and destroy biological activity. If a reconstituted vial accidentally freezes (e.g., in a shipping cold-chain failure), discard and reconstitute a fresh vial. The Clavicular Concurrent-Compound Stack The Clav looksmaxxing protocol runs three additional compounds concurrent with retatrutide from week 1. Each has a distinct role and dose rationale that does NOT follow the retatrutide escalation ramp — they stay at a stable dose throughout.	Compound	Vial Size	BAC Water	Concentration	Weekly Dose

Retatrutide	15 mg	5 mL	3 mg/mL	2 → 4 → 8 mg (escalating)
BPC-157	10 mg	10 mL	1 mg/mL	250 mcg/day (sub-q)
GHK-Cu	50 mg	10 mL	5 mg/mL	2 mg 3×/week (sub-q)
SNAP-8	5 mg	5 mL	1 mg/mL	Topical; varies

BPC-157 and GHK-Cu have decades of research history and no published escalation requirement. SNAP-8 is typically formulated topically rather than injected, so dosing math is application-based rather than volumetric.

BPC-157 — Concurrent GI Protection

The concurrent BPC-157 dosing in the Clav protocol is not decorative. The GI side-effect data from TRIUMPH-4 (43% nausea, 33% diarrhea in the retatrutide pooled arm) is the target BPC-157 addresses.

BPC-157 is a pentadecapeptide fragment derived from gastric juice protein BPCP-KP-90, first characterized by Sikirić et al. at the University of Zagreb in the 1990s. The published preclinical literature documents:

• Accelerated healing of gastric and duodenal ulcers
• Attenuation of NSAID-induced GI lesions
• Reduction in systemic inflammatory response during GI stress

The practical implication: BPC-157 at 250 mcg/day subcutaneously through the retatrutide escalation window is the Clav protocol's answer to the published GI tolerability data. It is started day 1 (not gated to retatrutide escalation steps) because its mechanism is GI-protective, not receptor-sensitization.

References & Further Reading

Primary literature:

• Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. The New England Journal of Medicine, 2023. Full text · PubMed
• Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet, 2023. PubMed
• Eli Lilly and Company. Retatrutide TRIUMPH-4 Phase 3 Topline Results — Press Release, December 2025. Investor release
• TRIUMPH-4: Retatrutide Delivers Weight Loss, Knee Osteoarthritis Pain Relief. HCPLive, 2025. HCPLive coverage
• Rheumatology Advisor. TRIUMPH-4 Results: Retatrutide Cuts Weight and Knee OA Pain. Coverage
• ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Participants With Obesity and Knee Osteoarthritis (TRIUMPH-4). NCT05929079

BPC-157 background:

• Sikirić P, Petek M, Rucman R, et al. A new gastric juice peptide, BPC. An overview of the stomach-stomach hypothesis. Journal of Physiology — Paris, 1993. (Foundational paper; accessible via PubMed literature searches.)

Clinical-data reporting:

• Lilly's phase 2 retatrutide results published in NEJM show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks. Eli Lilly investor release, 2023. Release

---

All information on this page is a summary of published research literature for laboratory-research reference only. Not medical advice. Not for human consumption. Products sold through affiliated storefronts are for research use only.